Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575507 | 1.00 | OPRD1 (0.67) | OPRD1OPRM1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL233715 | 1.00 | OPRD1 (0.67) | OPRD1OPRM1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4576571 | 1.00 | OPRD1 (0.67) | OPRD1OPRM1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL236139 | 1.00 | OPRD1 (0.67) | OPRD1OPRM1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4575467 | 1.00 | OPRD1 (0.67) | OPRD1OPRM1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18661816 | 1.00 | OPRD1 (0.67) | OPRD1OPRM1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL236138 | 1.00 | OPRD1 (0.67) | OPRD1OPRM1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8930430 | 0.93 | OPRM1 (0.58) | OPRD1OPRM1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8930437 | 0.93 | OPRM1 (0.58) | OPRD1OPRM1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8930446 | 0.93 | OPRM1 (0.58) | OPRD1OPRM1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004242-A1 | Oligomer-Diarylpiperazine Conjugates | NEKTAR THERAPEUTICS (US) | 2012-01-05 | — | — | US | claimed |
| JP-2011510078-A | — | — | 2011-03-31 | — | — | JP | claimed |
| EP-2249872-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | Nektar Therapeutics (US) | 2010-11-17 | — | — | EP | claimed |
| WO-2009094209-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-07-30 | — | — | WO | claimed |
| EP-2249872-B1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9314463-B2 | Oligomer-diarylpiperazine conjugates | NEKTAR THERAPEUTICS (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150335640-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS | 2015-11-26 | — | — | US | disclosed |
| US-9061026-B2 | Oligomer-diarylpiperazine conjugates | NEKTAR THERAPEUTICS (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140155412-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-06-05 | — | — | US | disclosed |
| US-20120004242-A1 | Oligomer-Diarylpiperazine Conjugates | NEKTAR THERAPEUTICS (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2249872-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | Nektar Therapeutics (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009094209-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20080125443-A1 | CARDIOPROTECTIVE DELTA OPIOID RECEPTOR AGONISTS AND METHODS OF USING SAME | ENTA HOLDING LLC | 2008-05-29 | — | — | US | disclosed |
| US-7314880-B2 | Cardioprotective delta opioid receptor agonists and methods of using same | MOUNT COOK BIOSCIENCES, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20040171622-A1 | Cardioprotective delta opioid receptor agonists and methods of using same | DMK PHARMACEUTICALS CORPORATION | 2004-09-02 | — | — | US | disclosed |
| WO-2004060321-A2 | CARDIOPROTECTIVE DELTA OPIOID RECEPTOR AGONISTS AND METHODS OF USING SAME | ARDENT PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155412-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | BIRC5, MTX2, IAPP | OPRD1 2294/4885OPRM1 574/4885CYP1A2 493/4885 |
| US-20040171622-A1 | Cardioprotective delta opioid receptor agonists and methods of using same | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885CYP1A2 2152/4885 |
| US-20120004242-A1 | Oligomer-Diarylpiperazine Conjugates | BIRC5, MTX2, IAPP | OPRD1 2294/4885OPRM1 574/4885CYP1A2 493/4885 |
| US-20080125443-A1 | CARDIOPROTECTIVE DELTA OPIOID RECEPTOR AGONISTS AND METHODS OF USING SAME | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885CYP1A2 2152/4885 |
| US-20150335640-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | BIRC5, MTX2, IAPP | OPRD1 2294/4885OPRM1 574/4885CYP1A2 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.